Cartesian Therapeutics Data From Phase 2 Study Of Descartes-08 Demonstrates 100% Lupus Low Disease Activity State Response Rate In Participants With Systemic Lupus Erythematosus
Benzinga Newsdesk 12 months ago
News
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced positive initial data from the ongoing Phase 2
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced positive initial data from the ongoing Phase 2 open-label trial of Descartes-08 in patients with systemic lupus erythematosus (SLE). Descartes-08, Cartesian's lead cell therapy candidate, is an autologous anti-B cell maturation antigen (BCMA) chimeric antigen receptor T-cell therapy (CAR-T).
100% LLDAS response rate observed in patients with SLE who received Descartes-08 in Phase 2 open-label trial reaching Month 3 follow-up (n=3)
Disease remission reported as DORIS response seen in 2 out of 3 patients reaching Month 3 follow-up (n=3)
Descartes-08 in SLE patients was observed to have a favorable safety profile supporting outpatient administration without the need for lymphodepleting chemotherapy
Myositis seamless adaptive clinical trial design provides potential opportunity for a single pivotal trial expected to commence in 1H26